INFIQ

Infinity Pharmaceuticals Inc

A biopharmaceutical company based in Cambridge, Massachusetts, that developed small-molecule cancer drugs, with its chief candidate being eganelisib (IPI-549), an oral medicine designed to reprogram immune cells to help the body fight tumors. Founded in 1995, it agreed in 2023 to merge with MEI Pharma, but when that deal collapsed the company filed for Chapter 11 bankruptcy and began winding down its operations. Its name, never officially explained, fits the biotech habit of evoking boundless possibility.

No 8-K or 6-K filings recorded.